KindlyMD (NASDAQ:NAKA) Shares Gap Down - Here's Why

Key Points

• KindlyMD shares gapped down from $4.08 to $3.76 at market open, currently trading at $4.74 with a volume of over 2 million shares.
• Analysts from Maxim Group have given KindlyMD a "buy" rating with a target price set at $8.00, reflecting a consensus rating.
• For the last quarter, KindlyMD reported a loss of ($0.34) earnings per share and generated $0.41 million in revenue, with significant negative margins and return on equity.

KindlyMD, Inc. (NASDAQ:NAKA - Get Free Report) gapped down before the market opened on Monday . The stock had previously closed at $4.08, but opened at $3.76. KindlyMD shares last traded at $4.74, with a volume of 2,139,033 shares.

Analyst Upgrades and Downgrades

Separately, Maxim Group assumed coverage on shares of KindlyMD in a research note on Wednesday, September 3rd. They issued a "buy" rating and a $8.00 target price for the company. One analyst has rated the stock with a Buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $8.00.

KindlyMD Stock Up 24.0%

The firm's 50-day moving average price is $9.99. The company has a market cap of $1.90 billion, a PE ratio of -5.88 and a beta of 34.05.

KindlyMD (NASDAQ:NAKA - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The company reported ($0.34) earnings per share for the quarter. KindlyMD had a negative net margin of 244.00% and a negative return on equity of 131.09%. The company had revenue of $0.41 million for the quarter.

KindlyMD Company Profile

Kindly MD, Inc (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.